Description
ARA-290 | Erythropoietin-Derived Tissue-Protective Peptide — Research Grade
ARA-290 (cibinetide) is a cyclic 11-amino acid peptide derived from the B-C loop of erythropoietin. It activates the innate repair receptor (IRR), a heterodimer of the EPO receptor and the beta-common receptor, without engaging classic EPO receptor homodimers responsible for erythropoiesis.
Mechanism of Action
- IRR activation — selective agonism of the innate repair receptor triggers tissue-protective and anti-inflammatory signalling
- No erythropoiesis — does not stimulate red blood cell production or elevate haematocrit, unlike full EPO
- Neuroprotection — reduces apoptosis in dorsal root ganglion neurons in neuropathy models
- Anti-inflammatory — decreases TNF-alpha, IL-6 and promotes regulatory T-cell activity in inflammatory models
Research Areas
ARA-290 has been studied in Phase II clinical trials for sarcoidosis-associated small fibre neuropathy, diabetic peripheral neuropathy, and chronic pain. European Phase II data showed significant improvement in corneal nerve fibre density and neuropathic pain scores.
For Research Use Only. Rainbow Peptide supplies ARA-290 exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. P. Brines –
ARA-290 for our innate repair receptor and neuroprotection research. Purity confirmed 98.7% by HPLC. TRAF6 modulation assay showed expected anti-inflammatory activity. COA was the best we’ve received for this peptide.
H. Lindqvist –
ARA-290 used in our tissue protection and pain research model. Purity >98%. Dissolved cleanly. IRR (innate repair receptor) binding confirmed. COA detailed. Fast delivery with cold pack intact.
W. Okafor –
Good quality ARA-290. Purity >98.3%. Our SOCS3 upregulation assay showed expected cytoprotective signaling. COA thorough. Will continue using Rainbow Peptide for our EPO-derived research peptides.